Thomas Jefferson University

Jefferson Digital Commons
Division of Cardiology Faculty Papers

Division of Cardiology

8-1-2016

Statins and Exercise Training Response in Heart Failure Patients:
Insights From HF-ACTION.
Jacob P. Kelly
Duke University Medical Center; Duke Clinical Research Institute

Allison Dunning
Duke Clinical Research Institute

Phillip J. Schulte
Mayo Clinic

Mona Fiuzat
Duke University Medical Center; Duke Clinical Research Institute
Follow this and additional works at: https://jdc.jefferson.edu/cardiologyfp

Eric S. Leifer

Part of
the Cardiology
Commons
National
Heart,
Lung, and Blood
Institute

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Kelly, Jacob P.; Dunning, Allison; Schulte, Phillip J.; Fiuzat, Mona; Leifer, Eric S.; Fleg, Jerome L.;
Cooper, Lawton S.; Keteyian, Steven J.; Kitzman, Dalane W.; Pina, Ileana L.; Kraus, William E.;
Whellan, David J.; O'Connor, Christopher M.; and Mentz, Robert J., "Statins and Exercise Training
Response in Heart Failure Patients: Insights From HF-ACTION." (2016). Division of Cardiology
Faculty Papers. Paper 63.
https://jdc.jefferson.edu/cardiologyfp/63
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Division of Cardiology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Jacob P. Kelly, Allison Dunning, Phillip J. Schulte, Mona Fiuzat, Eric S. Leifer, Jerome L. Fleg, Lawton S.
Cooper, Steven J. Keteyian, Dalane W. Kitzman, Ileana L. Pina, William E. Kraus, David J. Whellan,
Christopher M. O'Connor, and Robert J. Mentz

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/cardiologyfp/63

HHS Public Access
Author manuscript
Author Manuscript

JACC Heart Fail. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:
JACC Heart Fail. 2016 August ; 4(8): 617–624. doi:10.1016/j.jchf.2016.05.006.

Statins and Exercise Training Response in Heart Failure Patients
Insights From HF-ACTION
Jacob P. Kelly, MDa,b, Allison Dunning, MScb, Phillip J. Schulte, PhDc, Mona Fiuzat,
PharmDa,b, Eric S. Leifer, PhDd, Jerome L. Fleg, MDd, Lawton S. Cooper, MDd, Steven J.
Keteyian, PhDe, Dalane W. Kitzman, MDf, Ileana L. Pina, MDg, William E. Kraus, MDa,h,
David J. Whellan, MDi, Christopher M. O’Connor, MDa,b, and Robert J. Mentz, MDa,b

Author Manuscript

aDivision

of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North
Carolina
Clinical Research Institute, Durham, North Carolina cDepartment of Health
Sciences Research, Mayo Clinic, Rochester, Minnesota dDivision of Cardiovascular Science,
National Heart, Lung, and Blood Institute, Bethesda, Maryland eDivision of Cardiovascular
Medicine, Henry Ford Hospital, Detroit, Michigan fSection of Cardiology, Department of Internal
Medicine, Wake Forest University, Winston-Salem, North Carolina gDivision of Cardiology,
Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, New York,
New York hDuke Molecular Physiology Institute, Durham, North Carolina iDivision of Cardiology,
Thomas Jefferson University, Philadelphia, Pennsylvania
bDuke

Author Manuscript

Abstract
OBJECTIVES—The aim of this study was to assess for a treatment interaction between statin use
and ET response.
BACKGROUND—Recent data suggest that statins may attenuate exercise training (ET) response,
but limited data exist in patients with heart failure (HF).

Author Manuscript

METHODS—HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction
≤35% who were randomized to usual care with or without ET. We evaluated whether there was a
treatment interaction between statins and ET response for the change in quality of life and aerobic
capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also
assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in
these endpoints with ET. Multiple linear regression analyses were performed for each endpoint,
adjusting for baseline covariates.
RESULTS—Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at
baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology
but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence
of a treatment interaction between statin use and ET on changes in quality of life or exercise
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capacity, nor was there evidence of differential association between statin type and ET response
for these endpoints (all p values >0.05).
CONCLUSIONS—In a large chronic HF cohort, there was no evidence of a treatment interaction
between statin use and short-term change in aerobic capacity and quality of life with ET. These
findings contrast with recent reports of an attenuation in ET response with statins in a different
population, highlighting the need for future prospective studies. (Exercise Training Program to
Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)
Keywords
chronic heart failure; exercise training; heart failure with reduced ejection fraction; statins
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In recently updated lipid guidelines, statin use carries a Class I recommendation for
secondary prevention in patients with atherosclerotic cardiovascular disease and for primary
prevention in high-risk individuals (1,2). Statin use in heart failure (HF) patients is also
common. Statin use has a Class III recommendation for patients with HF without other
indications in the most recent U.S. and European HF guidelines (3–5). However, the most
common etiology of HF in most developed countries is atherosclerotic cardiovascular
disease.
Current guidelines recommend nonpharmacological interventions including aerobic exercise
training (ET) and cardiac rehabilitation (CR) in patients with chronic HF with reduced
ejection fraction (EF) (4). Although many patients with HF receive statins, and the use of ET
interventions are increasingly incorporated into a patient-centered treatment approach,
guidelines do not provide specific recommendations for a combined use strategy or
appropriate timing for initiating ET and statin therapy (6,7).
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Recent data, however, suggest that statins may attenuate the ET response in some
populations (8). For example, in overweight or obese patients with metabolic risk factors,
statins attenuated the improvement in muscle enzyme mitochondrial levels and
cardiorespiratory fitness with ET (8). Consistent with this finding, several small studies have
also shown statins to reduce skeletal muscle mitochondrial content and oxidative capacity
(9–12). HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise
Training) is the largest clinical trial to examine the effect of ET in patients with chronic HF
receiving contemporary optimal medical therapy (13). We performed a secondary analysis of
HF-ACTION to assess for a treatment interaction between statin use and response to ET
with respect to changes in aerobic capacity and health-related quality of life (HR-QoL) from
baseline to 3 months.
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METHODS
HF-ACTION was a multicenter, randomized, placebo-controlled trial of usual care with and
without an ET regimen in 2,331 patients with stable chronic HF. The study design and
results have been previously reported (13,14). The ET intervention included 36 supervised
sessions of aerobic exercise over 3 months, followed by home training on a treadmill or
stationary cycle for an additional 2 years. The usual care group received self-management
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educational materials with information on medications, fluid management, and sodium
intake and recommendations for 30 min of moderate-intensity physical activity most days of
the week as tolerated. Changes in baseline peak oxygen uptake (VO2) and 6-min walk
distance (6MWD) were analyzed at 3months to characterize exercise capacity. HR-QoL was
measured using the 23-item self-administered disease-specific Kansas City Cardiomyopathy
Questionnaire (KCCQ) at 3 months. Each participating center’s ethics committee or
institutional reviewboard approved the study, and all patients gave written informed consent.
The present analysis focuses on patients enrolled in HF-ACTION who were on statin
therapy at baseline compared with those not on a statin to evaluate for a treatment interaction
of statin therapy on ET response.
PATIENT POPULATION

Author Manuscript

Patients enrolled in HF-ACTION were required to have stable chronic HF with left
ventricular EF ≤35% and New York Heart Association functional class II to IV symptoms
while on optimal HF therapy for ≥6 weeks. Patients were excluded if they had major
comorbidities or other limitations that would preclude ET, devices that would prevent
achievement of target heart rates, or recent (≤6 weeks) or planned (≤6 months) major
cardiovascular procedures. For the present analysis, statin use was defined as HMG-CoA
reductase inhibitor use at baseline stratified by the specific statin marked on the case report
form: atorvastatin, pravastatin, simvastatin, or other. Other lipid-lowering agents were also
captured.
OUTCOMES OF INTEREST
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The primary outcomes for the present analysis were change in peak VO2 and change in
KCCQ from baseline to 3 months, as in previous HF-ACTION analyses, because of the
increased missingness at later time points (15,16). The secondary outcome was change in
6MWD from baseline to 3 months.
STATISTICAL ANALYSIS

Author Manuscript

We performed post-hoc analyses of patients with and without statin treatment at baseline to
assess their change in peak VO2, KCCQ, and 6MWD. The baseline characteristics, including
demographics, physical and laboratory findings, medical history, and therapies, were
summarized as frequencies and percentages for categorical variables and by medians and
25th and 75th percentiles for continuous variables in patients stratified by randomized
treatment (ET vs. usual care) and statin use (no statin vs. statin) (see Table 1). Comparisons
of baseline characteristics across statin use were conducted within each treatment group
using Student t tests or Wilcoxon tests for continuous variables and chi-square tests or Fisher
exact tests for categorical variables when appropriate.
Linear regression models were used in the analysis to examine the relationship between
statin use and change in the individual endpoints from baseline to 3 months. To account for
the missing data at 3 months for the outcomes of interest, inverse weighting for missingness
was performed. Specifically, subjects in the regression model were weighted by the inverse
of their probability of having a nonmissing response similar to recent analyses in HFACTION (15,16). This should reduce the bias that would have been present in a complete
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case analysis by assigning higher weight to observed data subjects who were similar to
subjects who were more likely to have missing data (15). Inverse propensity weighting was
also used to account for the nonrandom use of statin therapy at baseline (15). The final
weight used in the analysis is the inverse of the product of the probability for missingness
and the probability for statin use. To investigate for possible confounding variables, the
propensity for statin treatment model was selected using backward stepwise variable
selection methods (conservatively using p < 0.10 to enter and stay in the model) and further
included all variables previously used in multivariable HF-ACTION models (see Table 2
footnote) (17). In the weighted linear models, we assessed interactions between randomized
treatment and statin use for each outcome. From this model, we report the interaction p
value and adjusted effect estimates for statin use within randomized subgroups.
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Analysis of variance was used to examine the relationship between type of statin used and
the change in exercise capacity and HR-QoL endpoints. Patients were classified into 5
groups: no statin, atorvastatin, simvastatin, pravastatin, and other. If a significant difference
in outcomes by statin type was found, multiple comparison (Tukey) analysis was conducted
to determine what those differences were.
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Adherence to ET (defined as exercise >90 min/week for the first 3 months of the study) was
assessed in the subset of patients randomized to ET comparing statin and nonstatin patients.
This analysis evaluated for an interaction between statin use and exercise adherence in the
ET group. These analyses were weighted for missingness and nonrandom statin use and
adjusted for the same covariates as previously mentioned. Statistical significance was
assessed using 2-sided p values, with values <0.05 considered statistically significant. All
statistical computations were generated using SAS version 9.4 (SAS Institute Inc., Cary,
North Carolina).

RESULTS
Statin therapy was used in 1,353 (58%) patients at baseline in HF-ACTION. The baseline
characteristics of patients randomized to usual care or ET further dichotomized into those on
statin therapy versus those not on statins are presented in Table 1. Patients treated with
statins were more likely to be older men with hypertension, an ischemic etiology of HF,
peripheral vascular disease, an elevated blood urea nitrogen, and a lower heart rate.
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and beta-blocker
use were similar between statin and nonstatin patients, whereas mineralocorticoid antagonist
use was lower and implanted cardioverter-defibrillator use was higher in the statin-treated
patients.

Author Manuscript

Patients randomized to usual care had higher rates of missing data compared with those
randomized to ET at 3 months (Online Table 1). The changes in exercise capacity and HRQoL from baseline to 3 months stratified by statin use and randomized treatment group are
displayed in Tables 2 and 3 (statin type). There was no evidence for a treatment interaction
between statin use and ET on changes in quality of life or exercise capacity, nor was there
evidence of differential association between statin type and ET response for the endpoints
(all p > 0.05). Figure 1 presents statin use and change in Peak VO2, 6MWD, and KCCQ
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from baseline to 3 months as a function of statin use and ET status. Online Figure 1 displays
median and interquartile range of the changes in peak VO2, 6MWD, and KCCQ score on the
basis of type of statin. There was also no interaction between statin use and exercise
adherence with respect to exercise capacity or HR-QoL in patients randomized to ET
(interaction p values for peak VO2, 6MWD, and KCCQ of 0.44, 0.80, and 0.60, respectively)
(Table 4).

DISCUSSION

Author Manuscript

In the largest clinical trial of ET in patients with chronic HF, we evaluated for a treatment
interaction between statin use and ET with respect to changes in exercise capacity and HRQoL. We found that statin use was more prevalent in older men with hypertension, ischemic
heart disease, and implanted cardioverter-defibrillators, but these patients had similar use of
baseline guideline-directed medical therapy for HF compared with nonstatin patients. We
found no evidence that statin treatment attenuated the response to ET in patients with
chronic HF and reduced EF. Furthermore, various statins did not have a differential
association with changes in quality of life or exercise capacity with ET. Our findings suggest
that patients with HF on statin therapy who undergo ET do not have a blunted training
response compared with nonstatin patients.
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Previous studies suggest that statin use lowers mitochondrial content and oxidative capacity
(9–12). Furthermore, atorvastatin impairs exercise-mediated mitochondrial adaptations in
skeletal muscle and lowers running capacity in rodents (18,19). Many highly trained athletes
are intolerant of statin treatment related to increased muscle enzyme release from skeletal
muscle after significant endurance events such as marathons (20–23). However, limited data
exist on changes in aerobic capacity in patients on statin therapy (24). A recent study that
randomized 37 patients who were overweight or obese and at risk of metabolic syndrome to
12 weeks of aerobic ET with or without simvastatin demonstrated attenuated
cardiorespiratory fitness responses and decreased skeletal muscle mitochondrial content in
patients treated with simvastatin (8). However, 2 small studies evaluated the effects of 40 mg
daily atorvastatin and 80 mg daily simvastatin in healthy subjects on maximal exercise
capacity over 8 and 12 weeks of therapy, respectively, demonstrating no effect on maximal
oxygen consumption (25,26). A prospective study that evaluated 1,201 patients with
coronary artery disease undergoing 12 weeks of CR after an acute cardiac event found no
effect of statin therapy on ET response (27). An age/sex-appropriate similar increase in peak
oxygen consumption from CR in statin and nonstatin treatment was also found (+3.2 ± 3.7
ml/kg/min and +3.1 ± 3.7 ml/kg/min, respectively) (8,27). The STOMP (Statins on Skeletal
Muscle Function and Performance) study randomized 420 healthy patients to evaluate
symptoms, muscle strength, and exercise capacity in patients treated with atorvastatin or
placebo over 6 months (28). STOMP found that atorvastatin therapy did not decrease
endurance, aerobic capacity, or physical activity levels compared with placebo (change in
peak VO2: −0.8 ml/kg/min (−1.3 to −0.3 ml/kg/min )(Post Minus Baseline) and −0.8
ml/kg/min (−1.4 to −0.2 ml/kg/min)(Post Minus Baseline), respectively) (28). Although
these studies do not include patients with HF, they include patients who were on potent
statin therapies for up to 6 months without demonstrating an impaired response to ET. These
studies support our findings in the chronic HF population. Interesting, a study in rats already
JACC Heart Fail. Author manuscript; available in PMC 2017 August 01.
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undergoing ET that then had statin therapy added also found no attenuated response to
exercise (29).
In HF-ACTION, ET reduced rehospitalizations and improved quality of life, offering
significant benefits on top of guideline medical therapy for HF (13, 30, 31). With the recent
Centers for Medicare and Medicaid expansion of coverage for CR to beneficiaries with HF,
many patients are being referred for such care, including a sizeable proportion receiving
statins. Our results suggest that there is no apparent blunting of the response to aerobic ET
with concomitant statin use. Instead, the expanded CMS coverage for ET should be
welcomed as a new therapeutic option to improve exercise capacity and quality of life and to
potentially reduce hospitalizations.
STUDY LIMITATIONS
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This was a retrospective analysis from a clinical trial of ET; thus, cause and effect
relationships for statin therapy cannot be directly assessed. Although several small studies
have suggested that statin use affects muscle strength, this patient-level data was unavailable
for analysis in the HF-ACTION trial. Despite covariate adjustment, other measured and
unmeasured variables may have influenced these results. Overadjustment bias may be
present, as we do not know the timing of statin initiation relative to variables in the
propensity model; thus, future prospective studies are needed to externally validate our
findings. Prior statin use was not captured in the HF-ACTION trial. Thus, if a patient
discontinued statin therapy due to statin intolerance, whether self-reported or clinically
confirmed, prior to enrollment in HF-ACTION, they would be included in a nonstatin group
for the current analysis; this would bias our findings toward the null hypothesis given that up
to 15% of patients experience statin-related myalgias (32). It is plausible that these patients
may be more likely to experience attenuated gains in exercise capacity or quality of life in
response to ET when using statins. The inclusion and exclusion criteria of the HF-ACTION
trial prevents generalization to the entire HF population, including those with preserved left
ventricular EF and the very elderly. A final limitation is the modest increase in aerobic
capacity with ET in HF-ACTION, due in part to low training adherence.

CONCLUSIONS
The results from this retrospective analysis of the large HF-ACTION trial suggest that statin
therapy does not attenuate the improvement in aerobic capacity or quality of life response to
ET in patients with chronic HF and reduced EF. Future prospective studies examining the
effect of statin therapy on the responses to ET in the HF population are warranted to confirm
our findings.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE
ET and CR carry Class I and IIA recommendations, respectively, in patients with HF, but
are uncommonly prescribed and completed in patients with HF related to various barriers.
Our findings suggest that there does not appear to be an attenuated ET response in
patients with HF on statin therapy.
TRANSLATIONAL OUTLOOK
Statin use does not blunt the ET response in patients with HF and reduced EF who
engage in ET compared with nonstatin users. Future prospective studies are needed to
confirm these findings and include patients with HF and preserved EF.
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FIGURE 1. Statin Use and Change in Peak VO2, 6MWD, and KCCQ From Baseline to 3 Months
as a Function of Statin Use and Exercise Training Status

KCCQ = Kansas City Cardiomyopathy Questionnaire; VO2 = oxygen consumption; 6MWD
= 6-min walk distance.
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III/IV

67.6
25.2
4.9
2.3
25 (20–30)
30 (26–36)

None

1

2

≥3

LVEF, %

BMI, kg/m2

HF hospitalizations in previous 6 months

66.1

II

NYHA functional classification

55 (45–64)

Age, yrs

Nonstatin (n = 489)

30 (26–34)

25 (20–31)

2.4

2.8

18.3

76.5

36.9

63.1

82.1

31.6

21.1

63.3

58.9

9.7

69.8

25.0

21.4

62 (55–70)

Statin (n = 683)

Usual Care

0.01

0.35

<0.01

0.30

<0.01

<0.001

0.61

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

p Value

30 (25–35)

25 (20–30)

2.7

4.3

19.3

73.7

37.8

62.2

86.1

45.7

20.2

53.3

17.6

3.9

24.3

40.7

40.5

57 (48–66)

Nonstatin (n = 489)

30 (26–35)

25 (20–30)

1.8

4.5

18.7

74.9

37.5

62.5

80.1

30.6

22.1

68.0

58.8

8.0

71.5

26.6

22.2

61 (53–69)

Statin (n = 670)

Exercise Training

Author Manuscript

Baseline Characteristics

0.20

0.97

0.78

0.90

0.06

<0.001

0.45

<0.001

<0.001

<0.01

<0.001

<0.001

<0.001

<0.001

p Value

Author Manuscript

TABLE 1
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1.1 (0.9–1.4)
18 (14–25)
74.2
21.7
94.7
49.1
78.3
33.7
15.1

Creatinine, mg/dl

BUN, mg/dl

ACE inhibitor

Angiotensin-II receptor blocker

Beta-blocker

Aldosterone antagonist

Loop diuretic

ICD

Biventricular pacemaker

18.9

41.4

78.8

42.2

95.0

22.5

72.9

22 (16–30)

1.3 (1.0–1.6)

139 (137–141)

68 (62–76)

112 (100–126)

Statin (n = 683)

0.09

<0.01

0.85

0.02

0.80

0.72

0.61

<0.001

<0.001

0.55

0.007

0.73

p Value

18.8

35.6

76.1

50.1

93.0

22.9

77.1

19 (14–26)

1.1 (0.9–1.4)

139 (137–141)

72 (64–80)

112 (100–125)

Nonstatin (n = 489)

18.5

47.2

78.1

41.5

94.9

25.7

74.3

21 (16–29)

1.2 (1.0–1.5)

139 (137–141)

68 (62–76)

110 (100–126)

Statin (n = 670)

0.90

<0.001

0.43

<0.01

0.18

0.28

0.28

<0.001

<0.001

0.61

<0.001

0.65

p Value

ACE = angiotensin converting enzyme; BMI = body mass index; BUN = blood urea nitrogen; CCS = Canadian Cardiovascular Society; HF = heart failure; HR = heart rate; ICD = implantable cardioverterdefibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PVD = peripheral vascular disease; SBP = systolic blood pressure.

Values are median (interquartile range) or %.

139 (137–141)

72 (64–79)

110 (100–126)

Sodium, mmol/l

HR at rest, beats/min

SBP, mm Hg

Author Manuscript
Nonstatin (n = 489)

Author Manuscript
Exercise Training

Author Manuscript

Usual Care
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Author Manuscript

Author Manuscript
68.0 ± 20.6
No Statin

Statin

Exercise training

70.8 ± 20.2
65.6 ± 19.8

66.1 ± 20.7
Statin

72.5 ± 19.8

64.5 ± 21.3

361.0 ± 105.4

Statin
No statin

366.2 ± 99.1

360.5 ± 104.0

Statin
No statin

373.4 ± 109.6

14.6 ± 4.5

Statin
No statin

15.1 ± 4.8

14.7 ± 4.5

15.5 ± 5.1

Baseline

No statin

Statin

No statin

Statin Use
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−0.9 (−8.6 to
7)

0.3 (−1.5 to
2.1)

−7.96 (−17.0
to 1.1)

−5.1 (−14.2 to
4.0)

−0.11 (−0.4 to
0.2)

−0.22 (−0.6 to
0.1)

0.9 (−4.4 to 2.6)

−19.2 (−60.6 to 22.2)

−25.36 (−49.6 to −1.1)

0.34 (−1.7 to 2.4)

−0.13 (−1.0 to 0.7)

0.96

0.81

0.54

0.97

0.80

0.57

Adjusted*†
Interaction
p Value

0.16

0.66

0.68

Unweighted
and
Unadjusted
Interaction
p Value

Adjusted (via inverse probability weighting) for the following variables: Peak VO2: age, sex, race, income, Hispanic ethnicity, history of diabetes, peripheral vascular disease, number of heart failure

70.9 ± 20.1

−1.44 (−3.1 to
0.2)

68.5 ± 21.5

388.0 ± 103.2

396.1 ± 106.7

363.1 ± 107.1

386.9 ± 111.7

15.6 ± 4.8

16.0 ± 5.0

14.9 ± 4.8

16.2 ± 5.1

3 Months

Adjusted*
Interaction
p Value

receptor blocker use at baseline, smoking status, KCCQ clinical summary score at baseline, LVEF, CPX test duration, and BUN. Model also adjusted via propensity weighting for statin use at baseline and
missing exercise capacity measures at 3 months. KCCQ: age, sex, prior myocardial infarction, prior revascularization, history of diabetes, number of heart failure hospitalizations in prior 6 months, NYHA
functional classification at baseline, aldosterone antagonist at baseline, nonloop diuretic and loop diuretic use at baseline, insulin use at baseline, AICD at baseline, systolic blood pressure at baseline, resting

BMI, LVEF, CPX test duration, CPX test peak respiratory exchange ratio, BUN, and angiotensin-II receptor blocker use at baseline. Model also adjusted via propensity weighting for statin use at baseline
and missing exercise capacity measures at 3 months. 6MWD: age, sex, Hispanic ethnicity, prior revascularization, ischemic etiology, number of heart failure hospitalizations in prior 6 months, history of
hypertension, baseline ACE inhibitor dose, nonloop diuretic or loop diuretic use at baseline, nonloop diuretic and loop diuretic use, aldosterone antagonist use at baseline, biventricular pacemaker,
pacemaker, systolic blood pressure at baseline, resting heart rate (beats/min), BMI, KCCQ total summary score at baseline, CPX test heart rate reserve, CPX test heart rate (beats/min) at end of stage 2 of
the CPX test, CPX test rest ECG rhythm, CPX test peak respiratory exchange ratio, CPX test VeVCO2 slope, peak VO2, KCCQ quality of life score at baseline, loop diuretic use at baseline, angiotensin II

hospitalizations in prior 6 months, ischemic etiology, NYHA functional classification at baseline, aldosterone antagonist at baseline, pacemaker, resting heart rate (beats/min), KCCQ total symptom score at
baseline, KCCQ physical limitation score at baseline, heart rate at peak exercise (beats/min), CPX test resting ECG rhythm, CPX test peak oxygen pulse, CPX test VeVCO2 slope, insulin use at baseline,

*

Values are mean ± SD or effect estimate (95% confidence interval). Reference = no statin.

Usual care

Exercise training

Usual care

KCCQ

6MWD, m

Usual care

CPET peak VO2,
ml/min/kg

Exercise training

Randomized Treatment Group

Test

Unweighted
and
Unadjusted
Effect
Estimate
Adjusted* Effect Estimate

Author Manuscript

Statin Status and Changes in Exercise Capacity and Quality of Life From Baseline to 3 Months

Author Manuscript

TABLE 2
Kelly et al.
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

AICD = Automatic implantable cardioverter-defibrillator; BDI = Beck Depression Inventory; CPET = cardiopulmonary exercise test; CPX = cardiopulmonary stress test; ECG = electrocardiogram; KCCQ
= Kansas City Cardiomyopathy Questionnaire; VeVCO2 = minute ventilation/carbon dioxide production; VO2 = oxygen consumption; 6MWD = 6-min walk distance; other abbreviations as in Table 1.

Random effect adjustment for site.

†

heart rate (beats/min), LVEF, KCCQ physical limitation score at baseline, KCCQ social limitation score at baseline, BDI score at baseline, CPX test heart rate reserve, CPX test heart rate at peak exercise
(beats/min), CPX test resting ECG rhythm, CPX test peak oxygen pulse, ventricular conduction on CPX, peak VO2, loop diuretic use at baseline, angiotensin-II receptor blocker use at baseline, peripheral
vascular disease, biventricular pacemaker, atrial fibrillation/flutter, BUN, and BMI. Model also adjusted via propensity weighting for statin use at baseline and missing exercise capacity measures at 3
months.
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Author Manuscript

Author Manuscript

ANOVA = analysis of variance; other abbreviations as in Table 2.

Adjustment variables as in Table 2 compared with no statins.

*

0.20

Pravastatin
−0.68

−0.03

Other lipid lowering

−0.45

Simvastatin

Adjusted* Mean Change Peak VO2
(ml/min/kg)

Atorvastatin

Statin
0.13

ANOVA p Value

−0.58

1.07

1.59

3.42

Adjusted* Mean Change
KCCQ
0.18

ANOVA p Value

Author Manuscript

Type of Statin and Changes in Exercise Capacity and Quality of Life: Baseline to 3 Months

14.82

21.35

29.73

23.94

Adjusted* Mean Change
6MWD (m)

0.26

ANOVA p Value

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

0.65 (−1.11 to 2.41)

ET nonadherent

0.47

0.70

p Value

0.44

Interaction p Value

ET = exercise training; other abbreviations as in Table 2.

Adjustment variables as in Table 2.

*

Values are effect estimate (95% confidence interval). Reference = no statin.

0.58 (−2.38 to 3.54)

ET adherent

Adjusted* Peak VO2
Effect Estimate

−43.7 (−119.2 to
31.88)

2.87 (−34.90 to 40.64)

Adjusted* 6MWD
Effect Estimate

0.26

0.88

p Value

0.80

Interaction p Value

0.47 (−12.46 to 13.40)

−1.35 (−10.64 to 7.95)

Adjusted* KCCQ
Effect Estimate

0.94

0.78

p Value

0.60

Interaction p Value

Statin Use and Changes in Exercise Capacity and Quality of Life From Baseline to 3 Months on the Basis of Adherence to Exercise Training in the
Exercise Training Treatment Arm

Author Manuscript
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